Press Release Details

Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results

August 4, 2021 at 4:05 PM EDT

SEATTLE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2021.

“We had another strong quarter with 83% revenue growth over prior year,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “I am encouraged by our performance across the business and excited about the emerging data from our immune medicine platform, which we expect to monetize for multiple opportunities in research, diagnostics and drug discovery.”

Recent Highlights

  • Revenue of $38.5 million for the second quarter 2021, representing an 83% increase from the second quarter 2020
  • clonoSEQ clinical sequencing volume in the second quarter 2021 grew 75% versus prior year and 15% over the first quarter of 2021
  • Signed a license agreement with Vaccibody to leverage Adaptive Biotechnologies’ T-cell data to inform the development of a T-cell based SARS-CoV-2 vaccine
  • Signed an agreement with Moderna to use immunoSEQ T-MAP COVID to measure the T-cell response to their second generation COVID vaccine and their Zika vaccine
  • Published case control data in Lyme disease and completing enrollment in ImmuneSense study to enable T-Detect Lyme offering in our CLIA certified lab around year end
  • Advanced T-Detect pipeline in autoimmune diseases including Crohn’s and Ulcerative Colitis for IBD differential diagnosis, and generated new early signal in Multiple Sclerosis

Second Quarter 2021 Financial Results

Revenue was $38.5 million for the quarter ended June 30, 2021, representing an 83% increase from the second quarter in the prior year. Sequencing revenue was $18.6 million for the quarter, representing a 132% increase from the second quarter in the prior year. Development revenue was $20.0 million for the quarter, representing a 53% increase from the second quarter in the prior year.

Operating expenses were $88.3 million for the second quarter of 2021, compared to $57.9 million in the second quarter of the prior year, representing an increase of 53%.

Net loss was $49.3 million for the second quarter of 2021, compared to $33.5 million for the same period in 2020.

Adjusted EBITDA (non-GAAP) was a loss of $35.6 million for the second quarter of 2021, compared to a loss of $28.5 million for the second quarter of the prior year.

Cash, cash equivalents and marketable securities was $689.5 million as of June 30, 2021.

2021 Financial Guidance

Adaptive Biotechnologies expects full year 2021 revenue to be in the range of $148 million to $155 million, representing 54% growth at the mid-point of the range over full year 2020 revenue. This compares to Adaptive Biotechnologies’ previous outlook of $145 million to $155 million.

Webcast and Conference Call Information

Adaptive Biotechnologies will host a conference call to discuss its second quarter 2021 financial results after market close on Wednesday, August 4, 2021 at 4:30 PM Eastern Time. The conference call can be accessed at The webcast will be archived and available for replay at least 90 days after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Use of Non-GAAP Financial Measure

To supplement our unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net loss adjusted for interest and other income, net, income tax benefit (expense), depreciation and amortization and share-based compensation expenses. We have provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe it is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Adjusted EBITDA has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA does not reflect:

  • all expenditures or future requirements for capital expenditures or contractual commitments;
  • changes in our working capital needs;
  • income tax benefit (expense), which may be a necessary element of our costs and ability to operate;
  • the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;
  • the non-cash component of employee compensation expense; and
  • the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations.

In addition, Adjusted EBITDA may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

Beth Keshishian

Karina Calzadilla, Vice President, Investor Relations
Carrie Mendivil, Gilmartin Group

Adaptive Biotechnologies

Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)

  Three Months Ended June 30,  Six Months Ended June 30, 
  2021  2020  2021  2020 
Sequencing revenue $18,555  $7,985  $33,729  $17,454 
Development revenue  19,950   13,003   43,218   24,444 
Total revenue  38,505   20,988   76,947   41,898 
Operating expenses                
Cost of revenue  10,765   4,912   20,756   10,255 
Research and development  37,800   25,992   71,572   49,927 
Sales and marketing  23,216   14,332   43,820   28,339 
General and administrative  16,066   12,238   31,002   24,059 
Amortization of intangible assets  423   423   842   847 
Total operating expenses  88,270   57,897   167,992   113,427 
Loss from operations  (49,765)  (36,909)  (91,045)  (71,529)
Interest and other income, net  464   1,893   1,102   4,787 
Income tax benefit     1,481      1,804 
Net loss $(49,301) $(33,535) $(89,943) $(64,938)
Net loss per share attributable to common shareholders, basic and diluted $(0.35) $(0.26) $(0.64) $(0.51)
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted  140,359,317   127,383,582   139,667,380   126,720,986 

Adaptive Biotechnologies

Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)

  June 30, 2021  December 31, 2020 
Current assets        
Cash and cash equivalents $184,186  $123,436 
Short-term marketable securities (amortized cost of $413,965 and $564,036, respectively)  414,227   564,833 
Accounts receivable, net  14,174   10,047 
Inventory  18,612   14,063 
Prepaid expenses and other current assets  12,530   14,535 
Total current assets  643,729   726,914 
Long-term assets        
Property and equipment, net  75,235   39,692 
Operating lease right-of-use assets  92,067   99,350 
Long-term marketable securities (amortized cost of $91,177 and $118,429, respectively)  91,131   118,525 
Restricted cash  2,138   2,138 
Intangible assets, net  9,383   10,225 
Goodwill  118,972   118,972 
Other assets  719   598 
Total assets $1,033,374  $1,116,414 
Liabilities and shareholders’ equity        
Current liabilities        
Accounts payable $6,093  $3,237 
Accrued liabilities  13,539   13,162 
Accrued compensation and benefits  8,630   11,950 
Current portion of operating lease liabilities  4,833   3,529 
Current portion of deferred revenue  83,553   73,319 
Total current liabilities  116,648   105,197 
Long-term liabilities        
Operating lease liabilities, less current portion  103,774   104,333 
Deferred revenue, less current portion  119,642   163,618 
Total liabilities  340,064   373,148 
Commitments and contingencies        
Shareholders’ equity        
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at June 30, 2021 and December 31, 2020; no shares issued and outstanding at June 30, 2021 and December 31, 2020      
Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2021 and December 31, 2020; 140,663,755 and 137,646,896 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively  14   14 
Additional paid-in capital  1,294,506   1,253,971 
Accumulated other comprehensive gain  216   893 
Accumulated deficit  (601,555)  (511,612)
Total Adaptive Biotechnologies Corporation shareholders’ equity  693,181   743,266 
Noncontrolling interest  129    
Total shareholders’ equity  693,310   743,266 
Total liabilities and shareholders’ equity $1,033,374  $1,116,414 

Adjusted EBITDA

The following table sets forth a reconciliation between our Adjusted EBITDA and our net loss, the most directly comparable GAAP financial measure, for each of the periods presented (in thousands, unaudited):

  Three Months Ended June 30,  Six Months Ended June 30, 
  2021  2020  2021  2020 
Net loss $(49,301) $(33,535) $(89,943) $(64,938)
Interest and other income, net  (464)  (1,893)  (1,102)  (4,787)
Income tax benefit     (1,481)     (1,804)
Depreciation and amortization expense  2,905   1,998   5,576   3,976 
Share-based compensation expense  11,249   6,373   19,733   11,048 
Adjusted EBITDA $(35,611) $(28,538) $(65,736) $(56,505)


Keep up to date with Adaptive

Sign up to receive our press releases via email